Association of 2024–2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans
Top Cited Papers
- 23 October 2025
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 393 (16) , 1612-1623
Abstract
Amid the declining clinical severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and diminishing public uptake of annual coronavirus disease 2019 (Covid-19) vaccines, contemporary evidence on vaccine effectiveness against clinically relevant outcomes is needed. We conducted an observational study that used the electronic health records of the Department of Veterans Affairs to evaluate the effectiveness of the 2024-2025 Covid-19 vaccine among veterans who received the Covid-19 and influenza vaccines on the same day (164,132 participants) and in an active-comparator group of veterans who received the influenza vaccine only (131,839 participants), between September 3 and December 31, 2024. Participants were followed for 180 days or until the occurrence of an outcome, whichever came first. We used inverse-probability-weighted models to estimate vaccine effectiveness (calculated as 1 minus the risk ratio) against Covid-19-associated emergency department visits, hospitalizations, and deaths at 6 months. At 6 months of follow-up, the estimated vaccine effectiveness was 29.3% (95% confidence interval [CI], 19.1 to 39.2) against Covid-19-associated emergency department visits (risk difference per 10,000 persons, 18.3; 95% CI, 10.8 to 27.6), 39.2% (95% CI, 21.6 to 54.5) against Covid-19-associated hospitalizations (risk difference per 10,000 persons, 7.5; 95% CI, 3.4 to 13.0), and 64.0% (95% CI, 23.0 to 85.8) against Covid-19-associated deaths (risk difference per 10,000 persons, 2.2; 95% CI, 0.5 to 6.9). Vaccine effectiveness against a composite of these outcomes was 28.3% (95% CI, 18.2 to 38.2), with a risk difference per 10,000 persons of 18.2 (95% CI, 10.7 to 27.5). The Covid-19 vaccine was associated with decreased risks of these outcomes across prespecified subgroups defined according to age (75 years), the presence or absence of major coexisting conditions, and immunocompetence status. In this national cohort of U.S. veterans, the receipt of the 2024-2025 Covid-19 vaccine was associated with decreased risks of severe clinical outcomes. (Funded by the Department of Veterans Affairs.).Keywords
Funding Information
- U.S. Department of Veterans Affairs
This publication has 40 references indexed in Scilit:
- Cases, Hospitalization, and Mortality in COVID-19 and Influenza Among Veterans in 2022-2025 Influenza SeasonsJAMA Network Open, 2025
- Development and validation of a clinical prediction tool for non-receipt of updated COVID-19 vaccinesVaccine, 2025
- Consequences and Opportunities From Poor Uptake of COVID Vaccinations Despite Strong EvidenceJAMA, 2025
- Mortality in Patients Hospitalized for COVID-19 vs Influenza in Fall-Winter 2023-2024JAMA, 2024
- Is Vaccination Approaching a Dangerous Tipping Point?JAMA, 2024
- Nirmatrelvir and Molnupiravir and Post–COVID-19 Condition in Older PatientsJAMA Internal Medicine, 2023
- Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in EnglandThe Lancet Regional Health - Europe, 2023
- Association of Treatment With Nirmatrelvir and the Risk of Post–COVID-19 ConditionJAMA Internal Medicine, 2023
- Risk of Death in Patients Hospitalized for COVID-19 vs Seasonal Influenza in Fall-Winter 2022-2023JAMA, 2023
- Target Trial EmulationJAMA, 2022